Netupitant

Netupitant

Netupitant
Systematic (IUPAC) name
2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide
Clinical data
Legal status
  • Approved
Identifiers
PubChem CID:
ChemSpider
Chemical data
Formula C30H32F6N4O
Molecular mass 578.59 g/mol

Netupitant is an antiemitic drug. In the United States, the combination drug netupitant/palonosetron (Akynzeo) is approved by the Food and Drug Administration for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.[1]

Mechanism of action

Netupitant is a selective NK1 receptor antagonist.[2]

References

  1. ^ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy".  
  2. ^ Rizzi A, Campi B, Camarda V, Molinari S, Cantoreggi S, Regoli D, Pietra C, Calo G (2012). "In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist netupitant". Peptides 37: 86–97.